All News
52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores.
Synovial hypertrophy most responsive.
Hands and feet, wrist and knees most affected and responsive.
@RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa
Robert B Chao, MD doctorRBC ( View Tweet)
Novel composite DAPSA LDA +IGA < or = to 1 may be a reliable predictor in long-term PsA skin/joint response (and easier to get than PASDAS in clinic.) @AlexisOgdie #EULAR2022 POS0082 @RheumNow https://t.co/dmMjGcsIcm https://t.co/BHRlGenCyl
Dr. Rachel Tate uptoTate ( View Tweet)
Merola et al. BE COMPLETE trial of bimekizumab (dual 17A/17Fi) in TNF-IR PsA. Week 16 ACR50: 43.4% BKZ vs 6.8% PBO. Rapid response with separation from week 4. @RheumNow #EULAR2022 OP0255 https://t.co/ZaxAeePP6L https://t.co/D5mDdkno3c
Links:
Richard Conway RichardPAConway ( View Tweet)
Behrens et al. Izokibep (small molecular size IL17Ai, suggested to abrogate issues with tissue distribution of monoclonal abs) in PsA. ACR50 52% in 80mg, 48% in 40mg, 13% in PBO. @RheumNow #EULAR2022 https://t.co/FUS50ax79C https://t.co/e1n1RbNw1b
Links:
Richard Conway RichardPAConway ( View Tweet)
Michielsens et al T2T tapering of TNFi in AxSpA and PsA. 72% tapered, 28% discontinued TNFi. Month 12 LDA 69% vs 73%.Month 12 dose 53% vs 91%. Flares 85% vs 78%. Needed more NSAID 54% vs 24% and steroid 30% vs 17%. @RheumNow #EULAR2022 OP0261 https://t.co/EDBPOgg4sX https://t.co/ckPqaTdm4B
Links:
Richard Conway RichardPAConway ( View Tweet)
Large 5 country cohort study - No increased risk of hematologic malignancies (lymphoid or myeloid) in PsA pts treated with TNFi.
In PsA overall compared to general population - moderately increased underlying risk of hematologic malignancies.
@RheumNow #EULAR2022 ABST#OP0257 https://t.co/P846RupitR
Robert B Chao, MD doctorRBC ( View Tweet)
Female PsA patients on TNFi have reduced treatment effectiveness, LDA (vs males). #EULAR2022 POS0077 @RheumNow https://t.co/EwDwxUarNb https://t.co/W5xgQlrnlF
Dr. Rachel Tate uptoTate ( View Tweet)
#OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and AxSpa were associated with the usual suspects: Age, male, high disease activity and comorbidities. No specific bDMARDs was associated. Good news for our patients @RheumNow https://t.co/itzmwqKCrH
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Ok to taper?
In PsA and AxSpA pts on TNFi, a T2T w/ tapering strategy was non-inferior to a T2T w/o tapering.
69% of tapered group remained in LDA, 73% no-taper group in LDA after 12 months.
Taper group did use more NSAIDs, cDMARDs, steroids
@RheumNow #EULAR2022 ABST#OP0261
Robert B Chao, MD doctorRBC ( View Tweet)
Deep learning can be used to distinguish seropositive RA from seronegative RA and PsA based on MRI.
Early changes in PsO may suggest a PsA-like MRI pattern may be present!
Is this how we predict which PsO -> PsA?
@RheumNow #EULAR2022 ABST#OP0292 https://t.co/NGfFkSqlaM
Robert B Chao, MD doctorRBC ( View Tweet)
The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al
Dr. Antoni Chan synovialjoints ( View Tweet)
For psoriasis +MSK pain, should we be chasing synovitis/enthesitis on ultrasound?
PsO pts with MSK pain n=79
USS inflamm in 47%
Site-spec correlate only OR 3.1
Even if we act on USS:
PsA Rx is systemic, so overall impression is good enough anyway?
POS0131 #EULAR2022 @RheumNow https://t.co/O3P7J2Rskw
David Liew drdavidliew ( View Tweet)
#EULAR2022 OP0274
Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease:
⭐️9% with RA, 6% with PsA and AS in Western Australia
⭐️Decrease overall since 1985, but recent increase
⭐️Sharp rise of mycotic infections
⭐️No PJP, likely due to ppx
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
BE COMPLETE RCT
Bimekizumab vs. PBO in TNFiIR PsA pts
meets its primary criteria at 16wks w/
-ACR50 43%
-PASI 90 69%
and MDA achieved in 40+% pts
No new safety signal.
@RheumNow #EULAR2022 OP0255 https://t.co/QazYlzDqIc
Aurelie Najm AurelieRheumo ( View Tweet)
Merola et al. IL23i Risankizumab in PsA. Proportion achieving ACR20 week24 by subgroup. Effective across all groups. Similar irrespective of demographics, disease characteristics, concomittent meds, prior bDMARD use. @RheumNow #EULAR2022 POS1032 https://t.co/GAVKFpwCst
Richard Conway RichardPAConway ( View Tweet)
FAP tracer-based PET-CT ☄️ (68Ga-FAPI-04)
⚡️Detects metabolic activity and tissular inflammation
⚡️Correlates with MRI changes in PsA
⚡️Is associated
w/ progression of joint damage
⚡️Is sensitive to change
An exciting new imaging modality!
@RheumNow OP0256 #EULAR2022 https://t.co/16Z1R71YjC
Aurelie Najm AurelieRheumo ( View Tweet)
Risk of haematological malignancy in PsA
Nordic cohorts
*40 events, IR 67/100 000 person-years
*NO difference between PsA bionaive and TNFi treated
BUT *⬆️ in PsA vs. matched controls
*no difference between myeloid and lymphoid malignancies.
OP0257 #EULAR2022 @RheumNow https://t.co/oIojobgDP3
Aurelie Najm AurelieRheumo ( View Tweet)
Swedish study by Lindstrom U et al of over 3000 PsA patients matched with RA comparators showed that the length of time on MTX (PsA 4.5 and RA 4.4 years) before adding or switching to b/tsDMARD was identical in PsA (34%) and matched RA controls (33%) #EULAR2022 @RheumNow POS0073 https://t.co/Dwrz8RVMnh
Dr. Antoni Chan synovialjoints ( View Tweet)
Izokibep Phase 2 in active PsA at Wk 16 results (80mg dose):
⭐️ACR50 52%
⭐️PASI 90 50%
⭐️Resolution of enthesitis LEI 88%
⭐️Safety profile similar to what observed in PsO.
Promising for the enthesitis domain!
@RheumNow OP0258 #EULAR2022 https://t.co/Wm3MvVQzoP
Aurelie Najm AurelieRheumo ( View Tweet)
Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb
Dr. Antoni Chan synovialjoints ( View Tweet)
